Myths vs. Facts: Getting Vanflyta (Quizartinib) Covered by Humana in Georgia
Answer Box: Vanflyta Coverage by Humana in Georgia
Myth-busting reality: Vanflyta (quizartinib) coverage by Humana requires prior authorization with FLT3-ITD mutation testing, EKG monitoring protocols, and often step therapy through midostaurin first. Most denials stem from missing documentation, not automatic rejections.
Fastest path: Submit complete prior authorization with FLT3-ITD test